Published in Br J Pharmacol on May 01, 1999
The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol (2013) 5.74
Pharmacology of nociceptin and its receptor: a novel therapeutic target. Br J Pharmacol (2000) 1.97
Characterization of [Nphe(1)]nociceptin(1-13)NH(2), a new selective nociceptin receptor antagonist. Br J Pharmacol (2000) 1.18
[Nphe1,Arg14,Lys15]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor. Br J Pharmacol (2002) 1.14
Partial agonist behaviour depends upon the level of nociceptin/orphanin FQ receptor expression: studies using the ecdysone-inducible mammalian expression system. Br J Pharmacol (2003) 0.98
Inhibitory effect of nociceptin on [3H]-5-HT release from rat cerebral cortex slices. Br J Pharmacol (1999) 0.94
Modulation of 5-hydroxytryptamine efflux from rat cortical synaptosomes by opioids and nociceptin. Br J Pharmacol (2000) 0.94
Control of glutamate and GABA release by nociceptin/orphanin FQ in the rat lateral amygdala. J Physiol (2001) 0.90
Nociceptin, Phe(1)psi-nociceptin(1 - 13), nocistatin and prepronociceptin(154 - 181) effects on calcium channel currents and a potassium current in rat locus coeruleus in vitro. Br J Pharmacol (1999) 0.84
Pharmacological profiles of presynaptic nociceptin/orphanin FQ receptors modulating 5-hydroxytryptamine and noradrenaline release in the rat neocortex. Br J Pharmacol (2003) 0.81
BU08073 a buprenorphine analogue with partial agonist activity at μ-receptors in vitro but long-lasting opioid antagonist activity in vivo in mice. Br J Pharmacol (2014) 0.80
Effects of nociceptin and endomorphin 1 on the electrically stimulated human vas deferens. Br J Clin Pharmacol (2001) 0.79
Pharmacological profile of the cyclic nociceptin/orphanin FQ analogues c[Cys10,14]N/OFQ(1-14)NH2 and c[Nphe1,Cys10,14]N/OFQ(1-14)NH2. Naunyn Schmiedebergs Arch Pharmacol (2003) 0.79
Characterization of the ORL(1) receptor on adrenergic nerves in the rat anococcygeus muscle. Br J Pharmacol (2000) 0.78
Orphanin FQ/nociceptin and [Phe(1)Psi(CH(2)-NH)Gly(2)] nociceptin(1-13)-NH(2) stimulate gastric motor function in anaesthetized rats. Br J Pharmacol (2000) 0.78
In vitro pharmacological characterisation of a novel cyclic nociceptin/orphanin FQ analogue c[Cys(7,10)]N/OFQ(1-13)NH (2). Naunyn Schmiedebergs Arch Pharmacol (2007) 0.76
Cellular mechanisms of nociceptin/orphanin FQ (N/OFQ) peptide (NOP) receptor regulation and heterologous regulation by N/OFQ. Mol Pharmacol (2013) 0.76
Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature (1995) 6.72
Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor. Science (1995) 5.74
cDNA cloning of an orphan opiate receptor gene family member and its splice variant. FEBS Lett (1994) 1.72
Nociceptin/orphanin FQ and the opioid receptor-like ORL1 receptor. Eur J Pharmacol (1997) 1.51
A new selective antagonist of the nociceptin receptor. Br J Pharmacol (1998) 1.41
Increase by the ORL1 receptor (opioid receptor-like1) ligand, nociceptin, of inwardly rectifying K conductance in dorsal raphe nucleus neurones. Br J Pharmacol (1996) 1.40
Address and message sequences for the nociceptin receptor: a structure-activity study of nociceptin-(1-13)-peptide amide. J Med Chem (1997) 1.36
The effect of nociceptin on Ca2+ channel current and intracellular Ca2+ in the SH-SY5Y human neuroblastoma cell line. Br J Pharmacol (1996) 1.31
Intracerebroventricular orphanin FQ/nociceptin suppresses dopamine release in the nucleus accumbens of anaesthetized rats. Neuroscience (1996) 1.28
Opioid inhibition of Ih via adenylyl cyclase. Neuron (1994) 1.23
Nociceptin receptor coupling to a potassium conductance in rat locus coeruleus neurones in vitro. Br J Pharmacol (1996) 1.23
Actions of the ORL1 receptor ligand nociceptin on membrane properties of rat periaqueductal gray neurons in vitro. J Neurosci (1997) 1.17
Nociceptin inhibits T-type Ca2+ channel current in rat sensory neurons by a G-protein-independent mechanism. J Neurosci (1997) 1.12
Expression of alternate forms of brain opioid 'orphan' receptor mRNA in activated human peripheral blood lymphocytes and lymphocytic cell lines. Brain Res Mol Brain Res (1995) 1.10
Relationship between binding affinity and functional activity of nociceptin/orphanin FQ. Neuropeptides (1997) 1.09
Structure-activity relationship studies on the novel neuropeptide orphanin FQ. J Biol Chem (1996) 1.08
Pharmacological characterization of the nociceptin receptor mediating hyperalgesia in the mouse tail withdrawal assay. Br J Pharmacol (1998) 1.07
[Phe1psi(CH2-NH)Gly2]nociceptin-(1-13)-NH2 is an agonist of the nociceptin (ORL1) receptor. Eur J Pharmacol (1998) 1.07
Recognition and activation of the opioid receptor-like ORL 1 receptor by nociceptin, nociceptin analogs and opioids. Eur J Pharmacol (1997) 1.05
Distribution of nociceptin/orphanin FQ receptor transcript in human central nervous system and immune cells. J Neuroimmunol (1998) 1.04
Inhibition by nociceptin of neurogenic inflammation and the release of SP and CGRP from sensory nerve terminals. Br J Pharmacol (1997) 1.03
Structure-activity study of the nociceptin(1-13)-NH2 N-terminal tetrapeptide and discovery of a nociceptin receptor antagonist. J Med Chem (1998) 1.02
Nociceptin inhibits noradrenaline release in the mouse brain cortex via presynaptic ORL1 receptors. Naunyn Schmiedebergs Arch Pharmacol (1998) 1.01
[Phe1psi(CH2-NH)Gly2]-nociceptin-(1-13)NH2, a proposed antagonist of the nociceptin receptor, is a potent and stable agonist in the rat spinal cord. Neurosci Lett (1998) 1.01
Inhibition of tachykinin release from peripheral endings of sensory nerves by nociceptin, a novel opioid peptide. Br J Pharmacol (1996) 1.00
Biochemical evidence for orphanin FQ/nociceptin receptor heterogeneity in mouse brain. Biochem Biophys Res Commun (1997) 0.99
Pharmacological characterization of orphanin FQ/nociceptin and its fragments. J Pharmacol Exp Ther (1997) 0.99
Nociceptin induced inhibition of K+ evoked glutamate release from rat cerebrocortical slices. Br J Pharmacol (1996) 0.97
Naloxone-insensitive inhibition of acetylcholine release from parasympathetic nerves innervating guinea-pig trachea by the novel opioid, nociceptin. Br J Pharmacol (1997) 0.95
Interaction of [3H]orphanin FQ and 125I-Tyr14-orphanin FQ with the orphanin FQ receptor: kinetics and modulation by cations and guanine nucleotides. Mol Pharmacol (1997) 0.93
Nociceptin activation of the human ORL1 receptor expressed in Chinese hamster ovary cells: functional homology with opioid receptors. Eur J Pharmacol (1997) 0.93
Pharmacological studies on the "orphan" opioid receptor in central and peripheral sites. Can J Physiol Pharmacol (1998) 0.93
Functional selectivity of orphanin FQ for its receptor coexpressed with potassium channel subunits in Xenopus laevis oocytes. Mol Pharmacol (1996) 0.92
Orphanin FQ: receptor binding and analog structure activity relationships in rat brain. Life Sci (1996) 0.91
Regulation of mu-opioid receptor in neural cells by extracellular sodium. J Neurochem (1997) 0.87
The orphanin FQ system: an emerging target for the management of pain? Br J Anaesth (1998) 0.86
Pharmacological characterization of nociceptin receptor: an in vitro study. Can J Physiol Pharmacol (1997) 0.86
Depression of glutamatergic transmission by nociceptin in the neonatal rat hemisected spinal cord preparation in vitro. Br J Pharmacol (1996) 0.84
Nociceptin receptor binding in mouse forebrain membranes: thermodynamic characteristics and structure activity relationships. Br J Pharmacol (1998) 0.82
Rat central ORL-1 receptor uncouples from adenylyl cyclase during membrane preparation. Neurosci Lett (1998) 0.81
Inhibition by nociceptin of the light-evoked release of ACh from retinal cholinergic neurones. Br J Pharmacol (1997) 0.79
A developmental and genetic classification for malformations of cortical development. Neurology (2005) 3.50
TRPV3 is a temperature-sensitive vanilloid receptor-like protein. Nature (2002) 3.23
Terminology and classification of the cortical dysplasias. Neurology (2004) 2.99
Ketamine: its mechanism(s) of action and unusual clinical uses. Br J Anaesth (1996) 2.87
Classification system for malformations of cortical development: update 2001. Neurology (2001) 2.59
The Concise Guide to PHARMACOLOGY 2013/14: overview. Br J Pharmacol (2013) 2.48
Ethanol elicits and potentiates nociceptor responses via the vanilloid receptor-1. Nat Neurosci (2002) 2.43
Postoperative nausea and vomiting--time for balanced antiemesis? Br J Anaesth (2000) 2.10
Periventricular heterotopia: phenotypic heterogeneity and correlation with Filamin A mutations. Brain (2006) 2.00
Pharmacology of nociceptin and its receptor: a novel therapeutic target. Br J Pharmacol (2000) 1.97
Does shy-inhibited temperament in childhood lead to anxiety problems in adolescence? J Am Acad Child Adolesc Psychiatry (2000) 1.81
Natural history and prognosis of untreated stage I epithelial ovarian carcinoma. J Clin Oncol (1996) 1.78
Antimyoclonic effects of alcohol in progressive myoclonus epilepsy. Neurology (1990) 1.78
Periventricular heterotopia, mental retardation, and epilepsy associated with 5q14.3-q15 deletion. Neurology (2008) 1.74
Incorporation of labelled amino acids into the enkephalins. FEBS Lett (1977) 1.73
GLUT1 mutations are a rare cause of familial idiopathic generalized epilepsy. Neurology (2012) 1.67
Syndromes of bilateral symmetrical polymicrogyria. AJNR Am J Neuroradiol (2000) 1.66
Congenital bilateral perisylvian syndrome: study of 31 patients. The CBPS Multicenter Collaborative Study. Lancet (1993) 1.65
Regurgitation of gastric contents during general anaesthesia using the laryngeal mask airway. Br J Anaesth (1992) 1.64
Surgical resection for intractable epilepsy in "double cortex" syndrome yields inadequate results. Epilepsia (2001) 1.62
Protocadherin 19 mutations in girls with infantile-onset epilepsy. Neurology (2010) 1.59
Filamin A mutations cause periventricular heterotopia with Ehlers-Danlos syndrome. Neurology (2005) 1.57
Hypoxaemia during outpatient dental anaesthesia. Anaesthesia (1989) 1.50
Identification and characterisation of SB-366791, a potent and selective vanilloid receptor (VR1/TRPV1) antagonist. Neuropharmacology (2004) 1.48
Selectivities of opioid peptide analogues as agonists and antagonists at the delta-receptor. Br J Pharmacol (1984) 1.47
Effect of the laryngeal mask airway on lower oesophageal sphincter pressure in patients during general anaesthesia. Br J Anaesth (1992) 1.47
Characterization of mutations in the gene doublecortin in patients with double cortex syndrome. Ann Neurol (1999) 1.47
Neuropeptide S is a stimulatory anxiolytic agent: a behavioural study in mice. Br J Pharmacol (2008) 1.46
Spectrum of SCN1A mutations in severe myoclonic epilepsy of infancy. Neurology (2003) 1.45
I.v. anaesthetic agents inhibit dihydropyridine binding to L-type voltage-sensitive Ca2+ channels in rat cerebrocortical membranes. Br J Anaesth (1996) 1.44
The orphan opioid receptor and its endogenous ligand--nociceptin/orphanin FQ. Trends Pharmacol Sci (1997) 1.44
X-linked malformations of neuronal migration. Neurology (1996) 1.42
A new selective antagonist of the nociceptin receptor. Br J Pharmacol (1998) 1.41
Anandamide: an endogenous activator of the vanilloid receptor. Trends Pharmacol Sci (2000) 1.41
South African guidelines for the management of nocturnal enuresis. S Afr Med J (2003) 1.39
Facial hemangioma and cerebral corticovascular dysplasia: a syndrome associated with epilepsy. Neurology (2003) 1.39
Address and message sequences for the nociceptin receptor: a structure-activity study of nociceptin-(1-13)-peptide amide. J Med Chem (1997) 1.36
No interaction between the serotonin transporter polymorphism (5-HTTLPR) and childhood adversity or recent stressful life events on symptoms of depression: results from two community surveys. Am J Med Genet B Neuropsychiatr Genet (2007) 1.35
Dynorphin and dynorphin are ligands for the kappa-subtype of opiate receptor. Nature (1982) 1.35
Delta opioidmimetic antagonists: prototypes for designing a new generation of ultraselective opioid peptides. Mol Med (1995) 1.34
Increase in potencies of opioid peptides after peptidase inhibition. Eur J Pharmacol (1983) 1.31
Gabapentin inhibits the substance P-facilitated K(+)-evoked release of [(3)H]glutamate from rat caudial trigeminal nucleus slices. Pain (2001) 1.30
Activities of mixed NOP and mu-opioid receptor ligands. Br J Pharmacol (2007) 1.30
Effect of remifentanil on the haemodynamic response to orotracheal intubation. Br J Anaesth (1998) 1.28
Orexins: a new family of neuropeptides. Br J Anaesth (1999) 1.26
1,3-Biarylureas as selective non-peptide antagonists of the orexin-1 receptor. Bioorg Med Chem Lett (2001) 1.26
Presence and bronchomotor activity of protease-activated receptor-2 in guinea pig airways. Am J Respir Crit Care Med (2000) 1.24
Ketamine: new uses for an old drug? Br J Anaesth (2011) 1.23
Band heterotopia: correlation of outcome with magnetic resonance imaging parameters. Ann Neurol (1994) 1.22
Remifentanil--an opioid for the 21st century. Br J Anaesth (1996) 1.21
Clinical and molecular characteristics of 1qter microdeletion syndrome: delineating a critical region for corpus callosum agenesis/hypogenesis. J Med Genet (2008) 1.20
Morphine compared with diamorphine. A comparison of dose requirements and side-effects after hip surgery. Anaesthesia (1991) 1.18
Characterization of [Nphe(1)]nociceptin(1-13)NH(2), a new selective nociceptin receptor antagonist. Br J Pharmacol (2000) 1.18
Familial periventricular heterotopia: missense and distal truncating mutations of the FLN1 gene. Neurology (2002) 1.18
Characterization using FLIPR of rat vanilloid receptor (rVR1) pharmacology. Br J Pharmacol (2000) 1.18
Effects of remifentanil and alfentanil on the cardiovascular responses to induction of anaesthesia and tracheal intubation in the elderly. Br J Anaesth (2002) 1.17
Intracellular levels of the LIS1 protein correlate with clinical and neuroradiological findings in patients with classical lissencephaly. Ann Neurol (1999) 1.16
Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile. Br J Anaesth (2009) 1.15
Bilateral posterior periventricular nodular heterotopia: a recognizable cortical malformation with a spectrum of associated brain abnormalities. AJNR Am J Neuroradiol (2013) 1.14
Mutations in the oligophrenin-1 gene (OPHN1) cause X linked congenital cerebellar hypoplasia. J Med Genet (2003) 1.14
Familial perisylvian polymicrogyria: a new familial syndrome of cortical maldevelopment. Ann Neurol (2000) 1.13
Persistent postoperative pain: where are we now? Br J Anaesth (2011) 1.13
Inner dynein arm defects causing primary ciliary dyskinesia: repeat testing required. Eur Respir J (2011) 1.13
Intravenous immunoglobulin in neurological disease: a specialist review. J Neurol Neurosurg Psychiatry (2002) 1.13
Urodynamic and clinical evidence of acute inhibitory effects of intravesical nociceptin/orphanin FQ on detrusor overactivity in humans: a pilot study. J Urol (2001) 1.12
Further studies on the Dmt-Tic pharmacophore: hydrophobic substituents at the C-terminus endow delta antagonists to manifest mu agonism or mu antagonism. J Med Chem (1999) 1.11
Comparison of different doses of remifentanil on the cardiovascular response to laryngoscopy and tracheal intubation. Br J Anaesth (2000) 1.10
Effects of intravenous anesthetic agents on glutamate release: a role for GABAA receptor-mediated inhibition. Anesthesiology (2000) 1.10
Human doublecortin (DCX) and the homologous gene in mouse encode a putative Ca2+-dependent signaling protein which is mutated in human X-linked neuronal migration defects. Hum Mol Genet (1998) 1.09
Cannabinoid activation of recombinant and endogenous vanilloid receptors. Eur J Pharmacol (2001) 1.09
Characterization of nociceptin receptors in the periphery: in vitro and in vivo studies. Naunyn Schmiedebergs Arch Pharmacol (1999) 1.08
Longitudinal predictors of behavioural adjustment in pre-adolescent children. Aust N Z J Psychiatry (2001) 1.08
Postoperative myocardial ischaemia: temporal association with nocturnal hypoxaemia. Br J Anaesth (1991) 1.08
New ocular hazard of mode locking in CW lasers. Nature (1970) 1.07
Pharmacological characterization of the nociceptin receptor mediating hyperalgesia in the mouse tail withdrawal assay. Br J Pharmacol (1998) 1.07
Precursors of hyperactivity and aggression. J Am Acad Child Adolesc Psychiatry (1993) 1.05
Dose requirements, efficacy and side effects of morphine and pethidine delivered by patient-controlled analgesia after gynaecological surgery. Br J Anaesth (1996) 1.05
Genetic and neuroradiological heterogeneity of double cortex syndrome. Ann Neurol (2000) 1.05
Block by gabapentin of the facilitation of glutamate release from rat trigeminal nucleus following activation of protein kinase C or adenylyl cyclase. Br J Pharmacol (2001) 1.05
Functional studies of new GLA gene mutations leading to conformational Fabry disease. Biochim Biophys Acta (2009) 1.05
Evolution of the Dmt-Tic pharmacophore: N-terminal methylated derivatives with extraordinary delta opioid antagonist activity. J Med Chem (1997) 1.05
Effect of cisapride on morphine-induced delay in gastric emptying. Br J Anaesth (1987) 1.04
The effect of the pneumococcal toxin, pneumolysin on brain ependymal cilia. Microb Pathog (1999) 1.04
Mosaic mutations of the LIS1 gene cause subcortical band heterotopia. Neurology (2003) 1.04
Abnormal corticomuscular and intermuscular coupling in high-frequency rhythmic myoclonus. Brain (2003) 1.04
Angelman syndrome: correlations between epilepsy phenotypes and genotypes. Ann Neurol (1998) 1.04
The opioid receptors in the hamster vas deferens are of the delta-type. Neuropharmacology (1985) 1.03
Effect of prior administration of cold saline on pain during propofol injection. A comparison with cold propofol and propofol with lignocaine. Anaesthesia (1991) 1.03
Evidence that cholecystokinin induces immediate early gene expression in the brainstem, hypothalamus and amygdala of the rat by a CCKA receptor mechanism. Neuropharmacology (1994) 1.03
Structure-activity study of the nociceptin(1-13)-NH2 N-terminal tetrapeptide and discovery of a nociceptin receptor antagonist. J Med Chem (1998) 1.02
Nociceptin/orphanin FQ receptor ligands. Peptides (2000) 1.02